GLP-1 Analogues Market is expected to reach US$ 299.08 Billion by 2033 | Major Companies - Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc.

Market Size and Forecast:

The Glucagon-like Peptide 1 (GLP-1) Analogues Market size reached US$ 62.81 Billion in 2024 and is expected to reach US$ 299.08 Billion by 2033, growing at a CAGR of 17.6 % during the forecast period 2025-2033.

The Glucagon-like Peptide 1 (GLP-1) Analogues Market refers to the global industry focused on the research, development, production, and commercialization of GLP-1 receptor agonist drugs used primarily for type 2 diabetes and obesity management. These injectable or oral therapies mimic the natural GLP-1 hormone to regulate blood glucose levels, improve insulin secretion, delay gastric emptying, and promote weight loss. The market includes branded and pipeline products, manufacturers, distribution networks, and healthcare providers driving therapeutic adoption worldwide.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?sz

Recent Key Developments of United States:

✅ December 2025: Leading firms announced investments in next-gen oral GLP-1 formulations, targeting improved patient adherence over injectables.

✅ November 2025: U.S. manufacturers ramped up production capacity for GLP-1 drugs like semaglutide amid surging demand for obesity treatments, easing prior shortages. Eli Lilly expanded facilities to support tirzepatide supply chains.​

✅ October 2025: The FDA approved expanded labeling for GLP-1 analogues in cardiovascular risk reduction, boosting prescriptions beyond diabetes and weight loss. Market analysts noted a 15% quarterly sales surge driven by reimbursement updates.​

✅ September 2025: Novo Nordisk launched a nationwide patient access program for Wegovy, partnering with pharmacies to address affordability barriers in obesity care. Real-world evidence studies highlighted sustained weight loss efficacy.​

Recent Key Developments of Japan:

✅ November 2025: Ministry of Health announced incentives for domestic production of peptide-based GLP-1 drugs to cut import reliance, boosting local manufacturing.​

✅ October 2025: Hanmi Pharmaceutical and Glenmark launched clinical collaborations for next-generation GLP-1 agonists tailored to Asian populations.​

✅ September 2025: Auto-injector devices for GLP-1 receptor agonists hit USD 137.7 million in market value, with projections to USD 292.9 million by 2030 due to improved patient compliance.

✅ August 2025: Ozempic (semaglutide) received approval for obesity treatment under Japan's national insurance system, expanding access for adults aged 35-60.

List of the Key Players in the Glucagon-like Peptide 1 (GLP-1) Analogues Market:

Eli Lilly and Company
Novo Nordisk A/S.
Sanofi
AstraZeneca
Boehringer Ingelheim, Inc.
Glenmark Pharmaceuticals Ltd.
Hanmi Pharm.Co., Ltd.
Amgen Inc.
Gmax Biopharm.
Sciwind Biosciences Co., Ltd.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Glucagon-like Peptide 1 (GLP-1) Analogues Market:

By Product: Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Others.

By Type: Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist.

By Route of Administration: Subcutaneous, Oral.

By Application: Type 2 Diabetes Mellitus, Obesity, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Glucagon-like Peptide 1 (GLP-1) Analogues market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Glucagon-like Peptide 1 (GLP-1) Analogues Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Glucagon-like Peptide 1 (GLP-1) Analogues market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Glucagon-like Peptide 1 (GLP-1) Analogues Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Glucagon-like Peptide 1 (GLP-1) Analogues Market in 2025?
◆ What is the projected growth rate of the Glucagon-like Peptide 1 (GLP-1) Analogues Market through 2033?
◆ Who are the key players in the Glucagon-like Peptide 1 (GLP-1) Analogues Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.